Literature DB >> 11410615

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

R Riesenberg1, A Buchner, H Pohla, H Lindhofer.   

Abstract

Bispecific monoclonal antibodies (bsAbs) are a promising immunotherapeutic option for treatment of cancer, especially in situations of minimal residual disease. The combination of an anti-CD3 and anti-tumor-associated antigen antibody redirects cytotoxic T-lymphocytes towards malignant cells. Using a trifunctional bispecific antibody against EpCAM x CD3, that additionally activates Fc gamma R(+) accessory cells via its Fc region, we investigated the interaction between three EpCAM(+) prostate carcinoma cell lines and peripheral blood mononuclear cells (PBMCs) of healthy donors and patients with prostate carcinoma (PC). Visualization was performed by double immunocytochemical methods and computerized sequential video microscopy. Tumor cells and PBMCs supplemented with alpha EpCAM x alpha CD3 in 16-well chamber slides resulted in lysis of tumor cells within 1--3 days without any differences between patient and healthy donor PBMCs. The characteristic necrotic way of tumor cell killing (rounding, swelling, disrupting) could be observed in computerized sequences of video frames. Simultaneously, we could not reveal any form of apoptotic signal using three different apoptotic markers (TUNEL, M30 cyto death, anti-active caspase 3). Within the first 48 hr we observed typical PBMC cluster formation with increasing cell proliferation. PBMCs surrounding the tumor cells were not dominated by CD4(+), CD8(+), or CD14(+) cells. Lymphocytes with pore-forming perforin proteins concentrated towards the tumor target cells. Our combination of double immunocytochemical and computerized video microscopic techniques may serve as an important improvement of validity of cell-cell interaction experiments using in vitro models. (J Histochem Cytochem 49:911-917, 2001)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410615     DOI: 10.1177/002215540104900711

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  23 in total

1.  World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA.

Authors:  Eugen Dhimolea; Janice M Reichert
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

2.  A high-content screen for small-molecule regulators of epithelial cell-adhesion molecule (EpCAM) cleavage yields a robust inhibitor.

Authors:  Jana Ylva Tretter; Kenji Schorpp; Elke Luxenburger; Johannes Trambauer; Harald Steiner; Kamyar Hadian; Olivier Gires; Dierk Niessing
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

Review 3.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

4.  The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.

Authors:  Djordje Atanackovic; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Tobias Grob; Tim Luetkens; Sara Yousef; Yanran Cao; York Hildebrandt; Julia Templin; Katrin Bartels; Nesrine Lajmi; Heribert Stoiber; Nicolaus Kröger; Judith Atz; Diane Seimetz; Jakob R Izbicki; Carsten Bokemeyer
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 5.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

6.  Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.

Authors:  Kirsten Dettmar; Isabell Seitz-Merwald; Carsten Lindemann; Petra Schroeder; Diane Seimetz; Judith Atz
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

Review 7.  Catumaxomab: clinical development and future directions.

Authors:  Rolf Linke; Anke Klein; Diane Seimetz
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

8.  Structural and functional characterization of the trifunctional antibody catumaxomab.

Authors:  Dirk Chelius; Peter Ruf; Patrick Gruber; Matthias Plöscher; Reinhard Liedtke; Eva Gansberger; Juergen Hess; Michael Wasiliu; Horst Lindhofer
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 9.  Catumaxomab: in malignant ascites.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

10.  Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Authors:  Jalid Sehouli; Klaus Pietzner; Pauline Wimberger; Ignace Vergote; Per Rosenberg; Andreas Schneeweiss; Carsten Bokemeyer; Christoph Salat; Giovanni Scambia; Dominique Berton-Rigaud; Armando Santoro; Andrés Cervantes; Olivier Trédan; Christophe Tournigand; Nicoletta Colombo; Alexander S Dudnichenko; Anneke Westermann; Hilke Friccius-Quecke; Florian Lordick
Journal:  Med Oncol       Date:  2014-06-26       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.